Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FKBP1A | P62942 | 13/20 | 0.66 |
| ▸ | MTOR | P42345 | 1/20 | 0.63 |
| ▸ | FKBP4 | Q02790 | 1/20 | 0.63 |
| ▸ | FKBP5 | Q13451 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5834078 | 0.95 | FKBP1A (0.63) | FKBP1AMTORFKBP4FKBP5 | |
| SCHEMBL5834850 | 0.86 | FKBP1A (0.60) | FKBP1A | |
| SCHEMBL5834370 | 0.86 | FKBP1A (0.61) | FKBP1A | |
| SCHEMBL5833652 | 0.84 | FKBP1A (0.52) | FKBP1A | |
| SCHEMBL5834094 | 0.83 | FKBP1A (0.59) | FKBP1A | |
| SCHEMBL7614350 | 0.83 | FKBP1A (0.59) | FKBP1A | |
| SCHEMBL5834884 | 0.83 | FKBP1A (0.62) | FKBP1A | |
| SCHEMBL7460552 | 0.82 | FKBP1A (0.63) | FKBP1AMTORFKBP4FKBP5 | |
| SCHEMBL5834467 | 0.80 | FKBP1A (0.58) | FKBP1A | |
| SCHEMBL7761780 | 0.79 | FKBP1A (1.00) | FKBP1AMTORFKBP4FKBP5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7056935-B2 | Rotamase enzyme activity inhibitors | GPI NIL HOLDINGS, INC. (US) | 2006-06-06 | — | — | US | disclosed |
| US-20020052410-A1 | Administering to the animal suffering from neurological disorders an amide compound having an affinity for FKBP-type immunophilins | GLIAMED, INC. | 2002-05-02 | — | — | US | disclosed |
| US-20020042377-A1 | Rotamase enzyme activity inhibitors | GUILFORD PHARMACEUTICALS INC. | 2002-04-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020052410-A1 | Administering to the animal suffering from neurological disorders an amide compound having an affinity for FKBP-type immunophilins | FKBP14, FKBP1A, FKBP2 | FKBP1A 2/4885MTOR 942/4885FKBP4 5/4885 |
| US-20020042377-A1 | Rotamase enzyme activity inhibitors | BDNF, FKBP1A, FKBP14 | FKBP1A 2/4885MTOR 742/4885FKBP4 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.